Markets are always buzzing with action. Some of the biggest names in IT, finance, pharma, and infrastructure have announced key developments that could influence their stock performance. Whether it’s a new partnership, a major fundraising plan, or a regulatory approval, here is a quick look at the stocks that are in focus today, March 6.
Market recap
After a 10-day losing streak, Indian equity markets rebounded sharply on March 5, with the Nifty closing above 22,300. The Sensex surged 740 points or 1.01% to settle at 73,730, while the Nifty jumped 255 points or 1.15% to end at 22,337, marking a strong recovery for the indices.
Stocks to watch on March 06, 2025 TCS
Tata Consultancy Services (TCS) has teamed up with Vantage Towers, a leading telecom tower operator in Europe. They are launching a digital service platform to simplify processes for property owners leasing land for telecom towers. This will make it easier to manage sites and improve partnerships.
Wipro
IT giant Wipro has launched TelcoAI360, a platform designed to help telecom companies improve services using artificial intelligence (AI). The goal is to cut costs, enhance customer experience, and boost network security. The platform is built with support from ServiceNow and Wipro’s AI partners.
ALSO READUS Stocks-Wall Street closes lower as Trump sets 25% tariffs, manufacturing data dips LIC Housing Finance
LIC Housing Finance, a key mortgage lender, has approved a plan to raise Rs 1,22,500 crore in the next financial year. The funds will come from loans, bonds, commercial papers, and external borrowings to support its lending operations.
RPP Infra
Construction company RPP Infra Projects has secured a Rs 80.98 crore contract to improve Chennai’s water supply. The project involves building underground tanks, feeder mains, and distribution stations to strengthen water infrastructure in key areas.
Zydus Lifesciences
Pharma firm Zydus Lifesciences has received the final green light from the USFDA to sell Dasatinib tablets in multiple strengths. This is a generic version of Sprycel, a leukemia drug with $1.81 billion in annual US sales.
Hindustan Zinc
The board will meet on March 10 to discuss raising funds via listed non-convertible debentures on a private placement basis.
Kirloskar Industries
Mahesh Chhabria,
» Read More
